348 related articles for article (PubMed ID: 12799792)
1. [Possibilities and limits of immunotherapy in multiple sclerosis. Inflammatory and degenerative aspects of the disease require a new pathogenetic concept].
Kornhuber ME; Zierz S
Nervenarzt; 2003 Jun; 74(6):537-8; discussion 539. PubMed ID: 12799792
[No Abstract] [Full Text] [Related]
2. Newer long-term treatments for multiple sclerosis.
Pryse-Phillips W
Clin Neurol Neurosurg; 2002 Jul; 104(3):265-71. PubMed ID: 12127666
[No Abstract] [Full Text] [Related]
3. To treat, or not to treat: the therapeutic dilemma of idiopathic monosymptomatic demyelinating syndromes.
Frohman EM; Racke M; van Den Noort S
Arch Neurol; 2000 Jul; 57(7):930-2. PubMed ID: 10891973
[No Abstract] [Full Text] [Related]
4. [Pathogenesis and treatment of multiple sclerosis (state of the art in 2000)].
Zavalishin IA; Zhuchenko TD; Peresedova AV
Vestn Ross Akad Med Nauk; 2001; (7):18-22. PubMed ID: 11523422
[TBL] [Abstract][Full Text] [Related]
5. [Multiple sclerosis (MS), an inflammatory or degenerative disease?].
Confavreux C; Vukusic S
Presse Med; 2004 Feb; 33(3):151-2. PubMed ID: 15029024
[No Abstract] [Full Text] [Related]
6. Comment on Shuhaibar et al.: Favourable effect of immunomodulator therapy on bone mineral density in multiple sclerosis.
Kampman MT; Steffensen LH
Ir J Med Sci; 2009 Jun; 178(2):235-6; author reply 237-8. PubMed ID: 19184608
[No Abstract] [Full Text] [Related]
7. [Side-effects of the treatment with disease modifying drugs in patients with multiple sclerosis: an analysis of register data in the Yaroslavl region].
Spirin NN; Kasatkin DS; Stepanov IO; Shipova EG; Baranova NS
Zh Nevrol Psikhiatr Im S S Korsakova; 2012; 112(8):27-33. PubMed ID: 23096035
[TBL] [Abstract][Full Text] [Related]
8. [A comparative analysis of rebif 22-mcg and copaxone efficacy in multiple sclerosis].
Zavalishin IA; Peresedova AV; Stoĭda NI; Rebrova Oi; Zakharova MN; Adarcheva LS; Niazbekova AS; Askarova LSh; Baĭdina EV
Zh Nevrol Psikhiatr Im S S Korsakova; 2006; Spec No 3():111-5. PubMed ID: 17172245
[TBL] [Abstract][Full Text] [Related]
9. [Problems and prospects of beta-interferon and copaxone++ application in the treatment of multiple sclerosis].
Gusev EI; Boĭko AN; Pozer Ch
Zh Nevrol Psikhiatr Im S S Korsakova; 1999; 99(4):33-6. PubMed ID: 10319395
[No Abstract] [Full Text] [Related]
10. [Recommendations for the use of immunomodulatory drugs in multiple sclerosis: the BCTRIMS consensus] [Brazilian Committee for Treatment and Research in Multiple Sclerosis].
Tilbery CP; Moreira MA; Mendes MF; Lana-Peixoto MA
Arq Neuropsiquiatr; 2000 Sep; 58(3A):769-76. PubMed ID: 10973126
[TBL] [Abstract][Full Text] [Related]
11. Disease-modifying drugs for multiple sclerosis: a rapid and systematic review.
Clegg A; Bryant J; Milne R
Health Technol Assess; 2000; 4(9):i-iv, 1-101. PubMed ID: 10944743
[No Abstract] [Full Text] [Related]
12. Development of ulcerative colitis in a patient with multiple sclerosis following treatment with interferon beta 1a.
Schott E; Paul F; Wuerfel JT; Zipp F; Rudolph B; Wiedenmann B; Baumgart DC
World J Gastroenterol; 2007 Jul; 13(26):3638-40. PubMed ID: 17659718
[TBL] [Abstract][Full Text] [Related]
13. Disease modifying treatment in multiple sclerosis.
Fuller GN; Bone I
J Neurol Neurosurg Psychiatry; 2001 Dec; 71 Suppl 2(Suppl 2):ii20-1. PubMed ID: 11701780
[No Abstract] [Full Text] [Related]
14. [Diagnostics and drug therapy of multiple sclerosis].
Suomen Neurologinen Yhdistys ry
Duodecim; 2002; 118(13):1411-23. PubMed ID: 12239889
[No Abstract] [Full Text] [Related]
15. Immunologic therapy for relapsing-remitting multiple sclerosis.
MacLean HJ; Freedman MS
Curr Neurol Neurosci Rep; 2001 May; 1(3):277-85. PubMed ID: 11898530
[TBL] [Abstract][Full Text] [Related]
16. Guidance on new therapies in multiple sclerosis patients.
Gonsette RE
Lancet; 1996 Jul; 348(9020):136. PubMed ID: 8676708
[No Abstract] [Full Text] [Related]
17. The use of interferon Beta and glatiramer acetate in multiple sclerosis.
Goodin DS
Semin Neurol; 2013 Feb; 33(1):13-25. PubMed ID: 23709209
[TBL] [Abstract][Full Text] [Related]
18. Newer versus older treatments for relapsing-remitting multiple sclerosis.
Weinstock-Guttman B; Cohen JA
Drug Saf; 1996 Feb; 14(2):121-30. PubMed ID: 8852526
[TBL] [Abstract][Full Text] [Related]
19. Immunomodulatory treatment of MS in Slovenia.
Sega-Jazbec S
Clin Neurol Neurosurg; 2002 Jul; 104(3):249-50. PubMed ID: 12127663
[No Abstract] [Full Text] [Related]
20. Immune regulatory properties and interactions of copolymer-I and beta-interferon 1a in multiple sclerosis.
Zang Y; Hong J; Robinson R; Li S; Rivera VM; Zhang JZ
J Neuroimmunol; 2003 Apr; 137(1-2):144-53. PubMed ID: 12667659
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]